Merck & Co
Company Profile
Merck & Co. develops, manufactures and markets a broad variety of vaccines, prescription products, consumer products and animal health products worldwide. The company generates more than 55% of its annual revenues outside of the U.S. with almost 27% coming from Europe, the Middle East and Africa. Merck's R&D is focused on diseases such as Alzheimer's, diabetes and cancer. MRK shares are a component of both the S&P 500 and the Dow Jones Industrial Average.
Key Products & Services:
Claritin, Coppertone, Dr. Scholl's, Lotrimin, Gardasil, Pepcid, Cipro, Clarinex, Singulair, Propecia
Target Investor:
Style: 
What's this?
Risk: 
| Key Statistics* | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 |
|---|---|---|---|---|---|---|
| Revenue ($ millions) | $22,011.9 | $22,636.0 | $24,197.7 | $23,850.3 | $27,428.3 | $45,987.0 |
| EPS | $2.10 | $2.03 | $1.49 | $3.64 | $5.65 | $0.28 |
| Dividend | $1.52 | $1.52 | $1.52 | $1.52 | $1.52 | $1.52 |
* Acquired Schering-Plough in 2010
DRIP Plan Summary:
Shares Needed to Qualify: 1
Minimum Additional Investment: $50
Maximum Additional Investment: $50,000/year
Additional Purchase Discount: None
Purchase Trading Fee: $5 plus $0.01/share (by check)
$2 plus $0.01/share (by one-time automatic withdrawal)
Dividend Reinvestment Trading Fee: Company paid
Dividend Reinvestment Service Fee: 4%, maximum = $2
Plan Prospectus
Investor Contact Information:
Transfer Agent: Wells Fargo Shareowner Services
Mail:
Shareowner Relations Department
P.O. Box 64854
St. Paul, MN 55164
Phone: 800-522-9114
IR website: http://merck.com/investors/home.html?WT.svl=topnav
* By clicking this button you will initiate a share purchase request to other FirstShare community members.
